DNLI News and Press, Denali Therapeutics Inc. From 10/06/21

eIF2B activator DNL343 achieved safety and biomarker goals in a Phase 1 study in healthy volunteers; a Phase 1b study began in individuals with ALS in Q3 2021 Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to SAR443820/DNL788, a RIPK1 inhibitor, for th...

Denali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343 Sanofi to present Phase 2 study plans in ALS for RIPK1 inhibitor SAR443820 Denali to host analyst and investor webinar on October 6, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Cali...

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced the a...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this event. For further details see: Denali Therapeutics (DNLI) Presents At H.C. Wainwright 23rd Annual Global Investment Conference - Slideshow

Comparisons with DNLI are from hundreds of biotech product developers viewed continually by institutional investors as capital gain prospects. Including some held to be underpriced just days ago. Values are based on how market professionals protect their own capital, put at risk in or...

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced that ...

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced publicatio...

Gain’s cutting-edge precision medicine platform and novel compounds enable therapeutic access to previously undruggable targets. Public investors can access this disruptive technology at a venture-like valuation. A clean balance sheet funds the business until H2 2023, with ...

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial r...

Maximusnd/iStock via Getty Images A couple of merger deals sparked notable moves during Monday's midday action. A failed deal in the real estate sector sent shares of Willis Towers Watson (WLTW) reeling. Meanwhile, a sizable acquisition in the adult entertainment world gave a boost to RCI Hos...